# A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

> **NCT00312728** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 115 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Brain Neoplasms

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** First-Line Chemotherapy Agents
- **DRUG:** Second-Line Chemotherapy Agents

## Key facts

- **NCT ID:** NCT00312728
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2023-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312728, "A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00312728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*